Dec
15
2021
On demand

Current technological trends and advancements in vector purification

Demand for adeno-associated viral (AAV) vector-driven gene therapy space continues to grow, as the sector migrates into indications with larger patient population and dosage requirements. It is imperative that downstream processing doesn’t apply a handbrake to recent gains made in increasing upstream process scale and titer.

Next month, a Roundtable panel of industry AAV bioprocess experts including Ashish Saksule (Viral Vector Lead, Global Gene Therapy, Takeda) and Chantelle Gaskin (Field Application Scientist, Thermo Fisher Scientific) will join Cell & Gene Therapy Insights to discuss recent progress and future innovation needs for AAV purification.

  • What have been the key recent advances in AAV vector purification, and what are the most pressing current challenges?
  • How are the potentially conflicting drivers of increasing the efficiency versus the sensitivity/robustness of downstream vector processing reflected in today’s purification toolkit?
  • Where next in terms of the further development of the AAV downstream processing toolbox?

Chantelle Gaskin

Field Applications Scientist, Thermo Fisher Scientific

Chantelle is a Field Applications Scientist, specializing in protein and viral vector purification and downstream process development. She held leadership positions at Applied Genetic Technology Corporation and Brammer Bio, prior to joining the Thermo Fisher Scientific Bioproduction Division in 2020. With over 10 years of experience in gene therapy, Chantelle has accumulated comprehensive knowledge of standard industry practices and regulatory standards, applying this knowledge to advance development of therapies for a variety of indications including ocular, CNS and systemic disease.Chantelle holds a Master’s degree in Chemistry from University of Florida and a Bachelor’s in Chemistry from Smith College.

Ashish Saksule

Cell and Gene Therapy Process Development Lead, Takeda

Cell and Gene Therapy process development lead Technical expert on bioprocessing platforms for viral vectors (Lentivirus and Adeno-associated virus vector) and non-viral vectors with more than 7 years of experience. Ashish has graduate degree in Chemical Engineering from Michigan Tech University, and Biotechnology graduate degree from Harvard University. His experience spans research & drug development, clinical stage and CRO/CMO settings. Currently working at Takeda within Global Gene Therapy and have previously worked at MilliporeSigma and Miltenyi Biotec.

Nathalie Clement, PhD

Associate Professor, Courtesy Faculty, University of Florida, Gainesville,
FL AAV Gene Therapy Consultant, Unicorn Consultations, Gainesville, FL

Dr. Clement has more than 25 years of experience in the field of Gene Therapy, with a strong expertise in viral vectors, specifically adeno-associated vectors, in the academic and industry settings. Her research focus has strongly been focused on optimizing processes to support large-scale production of high quality rAAV stocks and their implementation into the GMP settings. During her thesis work at the University Libre of Brussels, Belgium, she developed new recombinant viruses derived from the parvovirus Minute Virus of Mice (MVM) for cancer-selective gene therapy treatments. She then joined Dr. Michael Linden’s laboratory at Mount Sinai School of Medicine, New York, where she developed novel recombinant AAV vectors and directed the AAV Vector Core. She next joined the Powell Gene Therapy Center in 2008 as the Associate Director to supervise AAV production and testing at research, preclinical and clinical grades. She led the Process and Development Group and the Quality Control group responsible for the production and release of all AAV pre-clinical and clinical lots. During her time at UF she oversaw manufacturing, release and stability campaigns of more than 7 AAV INDs from start to finish, including CMC preparations and interactions with FDA. More recently, she spent several months at Resilience, Alachua, Florida, as the Director of Process and Development of the Viral Vaccines and Gene Therapy franchises. IN that role she oversaw viral vaccine and AAV production scales up to 200L in suspension format and in the icellis 500 platform for adherent platforms of a variety of viruses and AAV vectors. Currently Nathalie is taking a break before starting a new adventure in 2022.

Ying Cai, PhD

Senior Director, Process Development, Ultragenyx Pharmaceutical

Ying Cai is the Sr. Director of Process Development at Ultragenyx Pharmaceutical. She heads AAV downstream process development and formulation development functions, also a CMC lead of AAV clinical programs. Prior to joining Ultragenyx, Ying worked at Sanofi, Biogen, Merck, and a few CDMOs. Ying has over 20 years’ experience in the development, validation, manufacturing and commercialization of different modalities including AAV, plasmid DNA, oligonucleotides, antibodies, antibody conjugates, and fusion proteins. Ying holds a Ph.D. in Chemical Engineering from the University of Arkansas at Fayetteville and a B.S. in Biochemical Engineering from Zhejiang University in China.

Matthew Roach

AAV Process Development Team Leader Precision BioSciences

Matt leads the AAV Process Development group at Precision BioSciences, which is focused on designing and implementing new strategies for the production and purification of adeno-associated virus. Matt completed his Bachelor's degree in Biological Sciences at North Carolina State University and his Master's degree in Microbiology and Cell Science at the University of Florida. Prior to Precision, Matt spent time at Pfizer working on the purification of AAV and the Biomanufacturing Training and Education Center training industry professionals on downstream bioprocessing operations.

SPEAKERS

Chantelle Gaskin
Field Applications Scientist, Thermo Fisher Scientific
Ashish Saksule
Cell and Gene Therapy Process Development Lead, Takeda
Nathalie Clement, PhD
Ying Cai, PhD
Senior Director, Process Development, Ultragenyx Pharmaceutical
Matthew Roach
AAV Process Development Team Leader, Precision BioSciences

You might also like

Simplifying analytical development for viral vector production: robust...

S Kashi Ranganath
Srinath Kashi Ranganath
Srinath Kashi Ranganath
Staff Scientist, Field Applications, Pharma Analytics Group at Thermo Fisher Scientific
3 Mar 2022
38
Days
17
Hrs
39
Min
Register

Introducing Lonza’s AAV suspension transient transfection platform to...

S Sanyal
Suparna Sanyal
Suparna Sanyal
Head of Viral Vectors Commercial Development at Lonza Pharma & Biotech
24 Feb 2022
31
Days
17
Hrs
39
Min
Register

AAV manufacturing process development using fast USP and DSP HPLC analytics

A Štrancar
Aleš  Štrancar
Aleš Štrancar
Chief Executive Officer at BIA Separations
17 Feb 2022
24
Days
17
Hrs
39
Min
Register

How to monitor protein impurities to ensure consistent cell and gene...

E Mørtz
Ejvind Mørtz
Ejvind Mørtz
Co-Founder & COO at Alphalyse
15 Feb 2022
22
Days
17
Hrs
39
Min
Register

TESSA technology: A new era for AAV manufacture

R Cawood
Ryan Cawood
Ryan Cawood
Chief Scientific Officer at OXGENE
10 Feb 2022
17
Days
17
Hrs
39
Min
Register